Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Novick, Diego | - |
dc.contributor.author | Montgomery, William | - |
dc.contributor.author | Haro, Josep Maria | - |
dc.contributor.author | Moneta, Maria Victoria | - |
dc.contributor.author | Zhu, Gang | - |
dc.contributor.author | Yue, Li | - |
dc.contributor.author | Hong, Jihyung | - |
dc.contributor.author | Duenas, Hector | - |
dc.contributor.author | Brugnoli, Roberto | - |
dc.date.available | 2020-02-28T06:43:24Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1178-2021 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9698 | - |
dc.description.abstract | Purpose: To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of <= 60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments. Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 patients with major depressive disorder without sexual dysfunction. The present analysis focused on a subgroup of patients from East Asia (n= 587). Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS were rated using the modified Somatic Symptom Inventory. A mixed model with repeated measures was fitted to compare the levels of functioning between duloxetine-treated (n= 227) and SSRI-treated (n= 225) patients, adjusting for baseline patient characteristics. Results: The mean SDS total score was similar between the two treatment cohorts (15.46 [standard deviation = 6.11] in the duloxetine cohort and 16.36 [standard deviation = 6.53] in the SSRI cohort, P= 0.077) at baseline. Both descriptive and regression analyses confirmed improvement in functioning in both groups during follow-up, but duloxetine-treated patients achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard error = 0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better functioning) than that of 6.76 (standard error = 0.77) in the SSRI cohort (P< 0.001). This treatment difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns were also observed for SDS subscores (work, social life, and family life). Conclusion: Depressed patients treated with duloxetine achieved better functioning compared to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS at baseline. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.relation.isPartOf | NEUROPSYCHIATRIC DISEASE AND TREATMENT | - |
dc.subject | EMERGENT SEXUAL DYSFUNCTION | - |
dc.subject | PAINFUL PHYSICAL SYMPTOMS | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | REMISSION RATES | - |
dc.subject | PRIMARY-CARE | - |
dc.subject | POOLED ANALYSIS | - |
dc.subject | DISORDER | - |
dc.subject | PLACEBO | - |
dc.subject | EFFICACY | - |
dc.title | Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000370920900001 | - |
dc.identifier.doi | 10.2147/NDT.S100675 | - |
dc.identifier.bibliographicCitation | NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.12, pp.383 - 392 | - |
dc.identifier.scopusid | 2-s2.0-84959245892 | - |
dc.citation.endPage | 392 | - |
dc.citation.startPage | 383 | - |
dc.citation.title | NEUROPSYCHIATRIC DISEASE AND TREATMENT | - |
dc.citation.volume | 12 | - |
dc.contributor.affiliatedAuthor | Hong, Jihyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | depression | - |
dc.subject.keywordAuthor | antidepressant | - |
dc.subject.keywordAuthor | duloxetine | - |
dc.subject.keywordAuthor | SSRI | - |
dc.subject.keywordAuthor | functioning | - |
dc.subject.keywordPlus | EMERGENT SEXUAL DYSFUNCTION | - |
dc.subject.keywordPlus | PAINFUL PHYSICAL SYMPTOMS | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | REMISSION RATES | - |
dc.subject.keywordPlus | PRIMARY-CARE | - |
dc.subject.keywordPlus | POOLED ANALYSIS | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.